Evaluating outcomes for patients with acute liver failure using MARS
Outcomes Using MARS: A Single Center Experience
This study looks at how well patients with acute liver failure or alcoholic hepatitis do after receiving dialysis treatment with a special system called MARS.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Sex | All |
| Sponsor | Methodist Health System Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT05594953 on ClinicalTrials.gov |
What this trial studies
This observational study involves a retrospective chart review of patients diagnosed with alcoholic hepatitis or acute liver failure at Methodist Dallas Medical Center. The research focuses on analyzing transplant-free survival and overall survival rates among patients who underwent at least one round of dialysis using the Molecular Adsorbent Recirculating System (MARS) from January 1, 2019, to December 15, 2020. Patient charts will be accessed through the EPIC system by the principal investigator or delegated personnel to gather necessary data for the study. The anticipated completion date for this study is January 31, 2022.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with alcoholic hepatitis or acute liver failure who have undergone dialysis using MARS.
Not a fit: Patients who do not meet the inclusion criteria, such as those without a diagnosis of alcoholic hepatitis or acute liver failure, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the effectiveness of MARS in improving survival rates for patients with acute liver failure.
How similar studies have performed: While this study is observational and retrospective, similar approaches have been used in other studies, but the specific use of MARS in this context may provide novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • The patient was diagnosed with: Alcoholic hepatitis; AoCLF; OR Acute fulminant liver failure • The patient underwent at least one round of dialysis using plasma exchange or MARSTM Exclusion Criteria: * Patient not meeting the inclusion criteria will be excluded. All patients who underwent MARS at MDMC will be included in the study population.
Where this trial is running
Dallas, Texas
- Methodist Dallas Medical Center — Dallas, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Parvez Mantry, MD — Methodist
- Study coordinator: Crystee Cooper, DHEd
- Email: clinicalresearch@mhd.com
- Phone: 214-947-1280
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.